OserLab

OserLab @DanaFarber @harvardmed Seeks To Identify New Targeted Therapies For Small Cell Lung Cancer. Tweets/Views are my own.

[AACR @AACR]

Small Cell Lung Cancer: Basic Mechanisms to Translational Advances—
Trudy G. Oliver, Matthew G. Oser, and Julien Sage will address this topic in a plenary at the AACR Conference on Lung Cancer (Jan 14-17; San Diego).
https://t.co/cE64QKPyh3
#AACRlung27 @Oser_Lab @SageJulien

[Journal of Clinical Investigation @jclinicalinvest]

EED helps small cell lung cancer keep its neuroendocrine state by repressing lung adenocarcinoma genes: https://t.co/DmaHA0nTyP

Matthew G. Oser @oser_lab & team @danafarber & @BrighamWomens report the polycomb scaffolding subunit EED as a key supporter of small-cell lung cancer neuroendocrine identity and EGFR-mutant lung adenocarcinoma-to-small-cell lung cancer transformation. Notably, inactivation of EED in mice impaired small cell lung cancer tumorigenesis.

The figure: EED inactivation promotes a shift from SCLC toward LUAD histology in an RPR2 GEMM in vivo.
@the_asci
#LungCancer #SCLC

[OserLab @Oser_Lab]

Beyond ASCL1, this study provides a generalizable framework for using complementary CRISPR-based screening approaches to dissect the regulation and function of lineage TFs in their endogenous cellular context. Congratulations to Keita, Kevin, and everyone involved in this work!

[OserLab @Oser_Lab]

Excited to share another new study from our lab, co-led by Keita Masuzawa and Kevin Dong: “A HUWE1 Regulatory Helix Gates ASCL1 Degradation Through Its C-Terminal Phospho-Degron in Small Cell Lung Cancer.”

https://t.co/SLhbNOAek3

[OserLab @Oser_Lab]

In this work, we combine genome-wide CRISPR knockout screening with base editor screening to identify regulators of ASCL1 protein abundance in SCLC and uncover a mechanism by which HUWE1 controls ASCL1 degradation through its C-terminal phospho-degron.

[OserLab @Oser_Lab]

Congratulations to Yixiang and everyone involved in this work and thank you to our funding sources @AmericanCancer.

[OserLab @Oser_Lab]

Excited to share new work from our lab: “Polycomb Scaffolding Subunit EED Supports the SCLC Neuroendocrine Identity and EGFR-Mutant LUAD to SCLC Transformation.”

https://t.co/gHFOST5Zq3

[OserLab @Oser_Lab]

This study was led by our fabulous postdoctoral fellow Yixiang Li, who drove the mouse modeling, wet-lab experiments, and bioinformatic analyses-a true tour de force! Yixiang is a K99 awardee and is currently on the faculty job market. He is an exceptionally talented!

[OserLab @Oser_Lab]

@KarunaMDPhD @Nature Beautiful study Karuna! Congrats!!Interesting to think about the potential parallels of this family in regulating plasticity across different cancer lineages.

[Bravo-Cordero Lab @BravoCorderoLab]

🚨We're growing! Our lab at @TischCancer is #recruiting postdocs for 3 fully funded NIH projects. If you want to explore the biology of tumor dormancy, join us!!! Projects focus on:🧠Cancer neuroscience, ECM-driven dormancy, HER2 biology.
📩 email for more info or send your CV👇

[OserLab @Oser_Lab]

Dear Colleagues,
In two weeks, I’ll ride the Pan-Mass Challenge (162 miles) for the second year in honor of my parents and everyone affected by cancer.100% of every donation supports cancer research at DFCI. Please consider donating. Thank you in advance!

https://t.co/cRKGBnsF33

[Lauren Averett Byers, MD @LaurenByersMD]

10th Anniversary!! of #SCLC U24 NCI Consortium meeting at @theNCI with @charlesrudin @PTRUJH Dr. John Minna Dr. Trudy Oliver @UTMDAnderson #SCLC #LCSM @UTSWCancerBio @NIH #plasticity #PDXs #SCLCsubtypes @SageJulien

[OserLab @Oser_Lab]

Excited to share our latest preprint, a wonderful collaboration w/ Matt Freedman and Sylvan Baca’s labs. Leveraging cfChIP-seq from patient plasma + functional mouse modeling, we uncover how TF subtype shapes response and resistance to tarlatamab in SCLC.
https://t.co/4nKW8PKe4D

[Sylvan Baca MD PhD (Hiring!) @SylvanBacaLab]

Our latest collaboration with #MattFreedman and @Oser_Lab on resistance to tarlatamab: https://t.co/3Ei2gYY3Gm. An exciting framework for studying cancer resistance: observations from patients using epigenomic #LiquidBiopsy -> functional validation in mouse models.

[OserLab @Oser_Lab]

It was wonderful visiting the Northwestern BMG Department today and learning about all the outstanding science going on here. Thank you @LuWangLab for the invitation!

[Northwestern BMG and SQE @NU_BMG_SQE]

Join us today for the BMG Seminar Speaker Dr. Matthew Oser! @Oser_Lab Hosted by Dr. Lu Wang @LuWangLab #epigenetics #Cancer #LungCancer @NUFeinbergMed @NorthwesternMed @DanaFarber @harvardmed

[OserLab @Oser_Lab]

Grateful to all of our collaborators including @yejingge at MDACC.
https://t.co/L6KF3PkMgy

[OserLab @Oser_Lab]

Excited to share our new work in Dev Cell (https://t.co/BjVkuDiBXi), led by my highly talented postdoc Deli Hong! We find that loss of NOTCH2 creates a dependency on TRIM28, highlighting TRIM28 as a potential therapeutic target in NOTCH2-deficient or low-NOTCH2 SCLC.

[OserLab @Oser_Lab]

@DrChoueiri @DanaFarber @Nature @DanaFarberNews @harvardmed @sands_jacob Thank you @DrChoueiri! Greatly appreciate your support and enthusiasm for this work!

[OserLab @Oser_Lab]

Please follow me on Bluesky: @matthewoser.bsky.social

[OserLab @Oser_Lab]

This study was led by my highly talented postdoctoral fellow Shilpa Singh and was an outstanding collaboration with Circle Pharma and Deepak Nijhawan's lab at UTSW. @DanaFarberNews @DFarberThoracic.

[OserLab @Oser_Lab]

Thrilled to share our new work published in Nature (https://t.co/6KIgZiDhMN). We report an exciting new potential therapeutic strategy with a fascinating mechanism of action for cancers with a compromised G1–S cell cycle checkpoint, including SCLC.
https://t.co/8UyaKWbecQ